Patients

Agios Pharmaceuticals, Inc. announced that it has submitted a New Drug Application (NDA) for Mitapivat to the U.S. Food and Drug Administration (FDA) for the treatment of adults with pyruvate…

Read. Learn. Empower. The Thalassaemia International Federation´s internationally acclaimed Educational Programme is a fundamental component of TIF´s work and is specifically designed for and addressed to the ever-growing learning needs…

The multi-stakeholder Blood and Beyond initiative recently published a policy briefing shedding light on how the COVID-19 pandemic affects blood use, blood transfusion services, and patients in whom transfusions are…

In occasion of the International Thalassaemia Day 2021, Ali Sattarpour, 45, France, Fédération SOS GLOBI Vice President and TIF’s Thalassaemia Patient Advocacy Group (T-PAG) Member, recounts a life of struggles,…

The Thalassaemia International Federation (TIF) expresses its disappointment about the outcome of the reimbursement negotiation process concerning gene therapy (Zynteglo™) for transfusion-dependent thalassaemia patients, announced last week. The Federation’s distress…

INTERNATIONAL THALASSAEMIA DAY 2021 – 8 MAY  ”Addressing Health Inequalities Across the Global Thalassaemia Community” Each year, individuals around the globe band together for one day of pure and empowering…

Global Blood Therapeutics, Inc. announced The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE Study of Oxbryta® (voxelotor) tablets in patients with sickle cell disease…

INTERNATIONAL THALASSAEMIA DAY 2021 – 8 MAY  ”Addressing Health Inequalities Across the Global Thalassaemia Community” Visit the International Thalassaemia Day page, now LIVE on TIF website, to find out why…

Hemanext Inc. announced today it has received a CE Certificate of Conformity for the CE Mark for its Hemanext ONE Red Blood Cell (RBC) Processing and Storage System, allowing the…